Early Antiinflammatory Therapy Attenuates Brain Damage After Sah in Rats.
early brain injury
methylprednisolone
minocycline
neuroprotection
subarachnoid hemorrhage
Journal
Translational neuroscience
ISSN: 2081-3856
Titre abrégé: Transl Neurosci
Pays: Germany
ID NLM: 101550327
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
02
2019
accepted:
18
03
2019
entrez:
18
5
2019
pubmed:
18
5
2019
medline:
18
5
2019
Statut:
epublish
Résumé
Early inflammatory processes may play an important role in the development of early brain injury (EBI) after subarachnoid hemorrhage (SAH). Experimental studies suggest that anti-inflammatory and membrane-stabilizing drugs might have beneficial effects, although the underlying mechanisms are not fully understood. The aim of this study was to investigate the effect of early treatment with methylprednisolone and minocycline on cerebral perfusion and EBI after experimental SAH. Male Sprague-Dawley rats were subjected to SAH using the endovascular filament model. 30 minutes after SAH, they were randomly assigned to receive an intravenous injection of methylprednisolone (16mg/kg body weight, n=10), minocycline (45mg/kg body weight, n=10) or saline (n=11). Mean arterial blood pressure (MABP), intracranial pressure (ICP) and local cerebral blood flow (LCBF) over both hemispheres were recorded continuously for three hours following SAH. Neurological assessment was performed after 24 hours. Hippocampal damage was analyzed by immunohistochemical staining (caspase 3). Treatment with methylprednisolone or minocycline did not result in a significant improvement of MABP, ICP or LCBF. Animals of both treatment groups showed a non-significant trend to better neurological recovery compared to animals of the control group. Mortality was reduced and hippocampal damage significantly attenuated in both methylprednisolone and minocycline treated animals. The results of this study suggest that inflammatory processes may play an important role in the pathophysiology of EBI after SAH. Early treatment with the anti-inflammatory drugs methylprednisolone or minocycline in the acute phase of SAH has the potential to reduce brain damage and exert a neuroprotective effect.
Sections du résumé
BACKGROUND
BACKGROUND
Early inflammatory processes may play an important role in the development of early brain injury (EBI) after subarachnoid hemorrhage (SAH). Experimental studies suggest that anti-inflammatory and membrane-stabilizing drugs might have beneficial effects, although the underlying mechanisms are not fully understood. The aim of this study was to investigate the effect of early treatment with methylprednisolone and minocycline on cerebral perfusion and EBI after experimental SAH.
METHODS
METHODS
Male Sprague-Dawley rats were subjected to SAH using the endovascular filament model. 30 minutes after SAH, they were randomly assigned to receive an intravenous injection of methylprednisolone (16mg/kg body weight, n=10), minocycline (45mg/kg body weight, n=10) or saline (n=11). Mean arterial blood pressure (MABP), intracranial pressure (ICP) and local cerebral blood flow (LCBF) over both hemispheres were recorded continuously for three hours following SAH. Neurological assessment was performed after 24 hours. Hippocampal damage was analyzed by immunohistochemical staining (caspase 3).
RESULTS
RESULTS
Treatment with methylprednisolone or minocycline did not result in a significant improvement of MABP, ICP or LCBF. Animals of both treatment groups showed a non-significant trend to better neurological recovery compared to animals of the control group. Mortality was reduced and hippocampal damage significantly attenuated in both methylprednisolone and minocycline treated animals.
CONCLUSION
CONCLUSIONS
The results of this study suggest that inflammatory processes may play an important role in the pathophysiology of EBI after SAH. Early treatment with the anti-inflammatory drugs methylprednisolone or minocycline in the acute phase of SAH has the potential to reduce brain damage and exert a neuroprotective effect.
Identifiants
pubmed: 31098320
doi: 10.1515/tnsci-2019-0018
pii: tnsci-2019-0018
pmc: PMC6487785
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104-111Références
Surg Neurol. 1975 Apr;3(4):214-8
pubmed: 806982
World Neurosurg. 2010 Jan;73(1):22-41
pubmed: 20452866
Mol Neurobiol. 2011 Feb;43(1):27-40
pubmed: 21161614
Neurol Med Chir (Tokyo). 1991 Jan;31(1):24-31
pubmed: 1712919
Jpn J Pharmacol. 2002 Mar;88(3):227-49
pubmed: 11949877
Stroke. 1995 Jul;26(7):1279-83; discussion 1284
pubmed: 7604426
J Cereb Blood Flow Metab. 2006 Nov;26(11):1341-53
pubmed: 16482081
Stroke. 1995 Jun;26(6):1086-91; discussion 1091-2
pubmed: 7762027
Lancet Neurol. 2011 Jul;10(7):618-25
pubmed: 21640651
Biomed Res Int. 2014;2014:384342
pubmed: 25105123
J Neurotrauma. 2011 Dec;28(12):2503-12
pubmed: 22013966
Neurosurgery. 2003 Jan;52(1):165-75; discussion 175-6
pubmed: 12493115
J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7
pubmed: 15674236
Neurol Res. 1999 Sep;21(6):585-92
pubmed: 10491821
JAMA Neurol. 2016 Jan;73(1):28-35
pubmed: 26552033
BMC Neurosci. 2009 Oct 06;10:126
pubmed: 19807907
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004583
pubmed: 16034939
Neuroscientist. 2005 Aug;11(4):308-22
pubmed: 16061518
J Neurosci Methods. 2008 Jan 30;167(2):327-34
pubmed: 17870179
Stroke. 1995 Apr;26(4):627-34; discussion 635
pubmed: 7709410
J Neurosurg. 2010 Mar;112(3):681-8
pubmed: 19522571
Neurol Res. 2006 Jun;28(4):399-414
pubmed: 16759443
J Neurosci Methods. 1980 Dec;3(2):129-49
pubmed: 6110810
Acta Neurochir Suppl. 2011;110(Pt 1):43-8
pubmed: 21116913
Cerebrovasc Dis. 2016;42(3-4):263-71
pubmed: 27173669
J Neurosurg. 2017 Jan;126(1):52-59
pubmed: 27035175
J Neurochem. 2012 Nov;123 Suppl 2:12-21
pubmed: 23050638
Pharmacotherapy. 2006 Apr;26(4):515-21
pubmed: 16553511
N Engl J Med. 1990 May 17;322(20):1405-11
pubmed: 2278545
Prog Neurobiol. 2012 Apr;97(1):14-37
pubmed: 22414893
J Neurosci. 2001 Apr 15;21(8):2580-8
pubmed: 11306611
Eur J Neurol. 2017 Apr;24(4):645-651
pubmed: 28213906
J Neurol Sci. 2016 Nov 15;370:312-319
pubmed: 27745692
J Neurosurg. 2009 May;110(5):996-1002
pubmed: 19061352
J Neuroendocrinol. 2012 Jan;24(1):174-82
pubmed: 21615563
Br J Pharmacol. 2013 May;169(2):337-52
pubmed: 23441623
Clin Pharmacokinet. 1988 Dec;15(6):355-66
pubmed: 3072140
Stroke. 2003 Dec;34(12):2807-11
pubmed: 14657545
J Neurosurg. 2008 Dec;109(6):1134-40
pubmed: 19035733
Neurol Res. 2002 Mar;24(2):215-22
pubmed: 11877907
J Neurosurg. 1983 Dec;59(6):925-32
pubmed: 6631514
Mini Rev Med Chem. 2012 Jan;12(1):44-52
pubmed: 22070692
Neurol Res. 2006 Jun;28(4):381-98
pubmed: 16759442
J Mol Endocrinol. 2002 Apr;28(2):69-78
pubmed: 11932204
J Neurosurg. 2004 Oct;101(4):633-40
pubmed: 15481718
J Mol Biol. 2010 Apr 23;398(1):83-96
pubmed: 20211188
Neurosurgery. 1987 Aug;21(2):157-60
pubmed: 3658126
Brain Res. 2005 May 17;1044(1):8-15
pubmed: 15862784
Mol Neurobiol. 2016 May;53(4):2668-78
pubmed: 26143258
J Neurol Sci. 1992 Aug;111(1):13-9
pubmed: 1402993
Brain. 2002 Jun;125(Pt 6):1297-308
pubmed: 12023318
Acta Neurochir Suppl. 2011;110(Pt 1):71-4
pubmed: 21116918
Acta Neurochir Suppl. 2013;115:185-92
pubmed: 22890667
J Neurosurg. 1995 Jan;82(1):55-62
pubmed: 7815135
Cerebrovasc Dis. 2013;35(2):131-7
pubmed: 23406891
Neurosci Lett. 2006 May 8;398(3):195-200
pubmed: 16469440